TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04899856

Intervention type: DEVICE
Group type: OTHER
Intervention: TransAeris
Description: TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransAeris
Description: TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
Study: NCT05399810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Application (ICOGNI) Training
Description: Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
Study: NCT06777173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg interferon alfa-2b
Description: NA combined with Peg interferon alfa-2b
Study: NCT06777277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: The intervention will be delivered in 16, 60-minute sessions (1st session 90 mins). The treatment manual was informed by a 12-session (75 min each) CBCT developed by our team for genito-pelvic pain. The SIAD manual focuses on empirically supported interpersonal factors relevant to SIAD, informed by the Interpersonal Emotion Regulation Model of women's sexual dysfunction. The goals of the CBCT are to: (1) re-conceptualize low sexual desire/arousal as multidimensional in which both partners affect and are affected by the SIAD symptoms (2) modify and/or accept those factors that are associated with low sexual desire/arousal to increase adaptive coping, facilitate sexual desire/arousal, and reduce sexual distress, (3) as per our theoretical model, improve couple interactions related to sexuality (e.g., communication, intimacy) via enhanced emotion regulation, and (4) consolidate skills.
Study: NCT06773923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL Scaffold
Description: patients with their jaw/maxilla in which the 3D scaffold with PCL will be inserted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE + Bio-Oss®
Description: patients with jaw/maxilla which will be regenerated using the conventional technique using a titanium reinforced polytetrafluoroethylene (PTFE) membrane (Cytoplast® brand) and filling the space with Bio-Oss xenograft (Geistlich
Study: NCT06775210

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: supportive sleep care
Description: sleep bundle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care bundle
Description: sleep bundle
Study: NCT06777355

Intervention type: OTHER
Intervention: Transthoracic and Transesophageal echography within 24 hours post cardiac surgery
Description: Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
Study: NCT06777121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder exercises + Thoracic extension exercise
Description: Shoulder exercises and thoracic extension exercises were performed 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder exercises + Thoracic kinesio taping
Description: In addition to shoulder exercises, thoracic kinesio taping was applied. Shoulder exercises were performed 5 days a week for 3 weeks. TKT was applied once a week and remained in place for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder exercises
Description: Shoulder exercises were performed. They were performed 5 days a week for 3 weeks.
Study: NCT06775561

Intervention type: GENETIC
Intervention: PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.
Description: Samples are collected by UO1/UO2/UO3. DNA/RNA samples are sent to UO3 for genome and transcriptome sequencing. In vitro systems or patient-derived cell models are used for in vitro experimental validation (UO2) or development of therapeutical approaches (UO2/UO4). Samples of cases still undiagnosed after the combined sequencing and validation approaches undergo long-read sequencing by an outsourcing facility. Sequencing data are transferred to UO1 for bioinformatic analysis and may be deposited into RDconnect for still inconclusive cases. Variants of interest from bioinformatic analyses and in vitro validations are collectively discussed by UO1/UO2/UO3 to evaluate their clinico-molecular significance and to be selected for testing therapeutic approaches by UO2/UO4. Blue arrows and shapes denote samples and personal data, while green data that make no identifiable person.
Study: NCT06773897

Intervention type: GENETIC
Intervention: Saliva sample
Description: Saliva sample is sent via prepaid US Mail for DNA extraction

Intervention type: GENETIC
Intervention: Saliva sample
Description: Saliva sample is sent via prepaid US Mail for DNA extraction

Intervention type: OTHER
Intervention: Health Surveys
Description: Health surveys are filled out online in the study portal.

Intervention type: OTHER
Intervention: Health Surveys
Description: Health surveys are filled out online in the study portal.
Study: NCT06777407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Intervention to Reduce Psychological Distress
Description: The brief mindfulness-based intervention is an eight-week training program designed for groups of 15 to 20 participants. The weekly sessions will last 90 minutes for the first session and 60 minutes for the following seven sessions. The program will be led by a certified mindfulness trainer, who is not part of the research team and will be solely responsible for training-related activities.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducational brochure
Description: Information on self-care and managing psychological distress will be provided. Once the study is completed and the data has been collected, participants in the control group will receive the intervention.
Study: NCT06775483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016
Description: Administered intravenously according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016
Description: Administered intravenously according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016
Description: Administered intravenously according to protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016
Description: Administered intravenously according to protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously according to protocol.
Study: NCT06775197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial meniscal replacement with Spongioflex®
Description: for any surgical procedure, the patient receives an antibiotic shot NIMP) just before surgery. The patient will be arthroscopically treated via the arthroscopic portal with implantation of a demineralized bone block (IMP: Spongioflex ®, appropriate size (DIZG gGmbH, Berlin, Germany)) as a partial meniscus substitute. The block will be adapted to the defect size and secured with 2-4 inside-out sutures (Etibond 0, Ethicon, Somerville, NJ). No dosing, the IMP has no systemic effect. The surgery (Intervention) will last between 60-90 minutes. The hospital stay is between 2-3 days after surgery. Follow-up visits: at the end of the hospital stay, after 6 weeks, after 6, 12 and 24 months and after 5 years for the operated group.
Study: NCT05026242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almond intervention
Description: Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be provided with isocaloric snacks
Study: NCT06336707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion
Study: NCT04766918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection with high molecular weight hyaluronic acid
Description: Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sono-guided injection with low molecular weight hyaluronic acid
Description: Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
Study: NCT06776497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIRTUAL REALITY GLASSES (VRG)
Description: Individuals who met the inclusion criteria and signed the informed consent form were assigned to the study groups based on a list which was numbered and generated in the computer environment before the arteriovenous fistula (AVF) procedure. According to the results given by the computer programme, the individuals were assigned to the control group and the virtual realitiy group (VRG)group. While the control group included patients who underwent AVF procedure with the standard method, the virtual reality headset group included patients who underwent AVF procedure during the VRG application.
Study: NCT05092711

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .

Intervention type: DRUG
Intervention: Observation
Description: Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
Study: NCT05205785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human Milk Oligosaccharide Mix
Description: Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
Study: NCT06547853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Groups will be enrolled in a 12-week exercise program. The intervention will be carried out in a highly complex oncology center in Maceió-AL, using the FITT components of the prescription: frequency (4 days a week), intensity (aerobic part through musical beats, subjective perception scale and resistance exercises through a number of maximum repetitions), the time of each session will be 45 minutes, the type of activity offered will be combined exercise training and aerobic exercise training (i.e., walking).
Study: NCT05336279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
Description: TR Group: famitinib malate T on day 1, famitinib malate R on day 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
Description: RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
Study: NCT06044558

Intervention type: DRUG
Intervention: Combined with voriconazole
Description: Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.

Intervention type: DRUG
Intervention: Combined with caspofungin
Description: Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.

Intervention type: DRUG
Intervention: Tacrolimus-alone treatment
Description: Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
Study: NCT06777186

Intervention type: OTHER
Intervention: 10 meter walk test
Description: The dual task skills of the individuals will be evaluated by adding motor and cognitive tasks to the 10-meter walk test. Tasks given to individuals~Single motor task (comfortable walking): The individual is asked to walk at normal speed, the time is recorded Motor-motor dual task: Both hands carry a half-full water bottle, time is recorded Motor-cognitive dual task (mental) : counts backwards from 10 by 1, time is recorded Motor - cognitive dual task (memory) : The individual is asked to say 3 words that were previously spoken. The time is recorded.
Study: NCT06078488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized and Protocolized Nutritional Care Bundle
Description: Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Standard Care
Description: Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
Study: NCT06777186

Intervention type: OTHER
Intervention: 10 meter walk test
Description: The dual task skills of the individuals will be evaluated by adding motor and cognitive tasks to the 10-meter walk test. Tasks given to individuals~Single motor task (comfortable walking): The individual is asked to walk at normal speed, the time is recorded Motor-motor dual task: Both hands carry a half-full water bottle, time is recorded Motor-cognitive dual task (mental) : counts backwards from 10 by 1, time is recorded Motor - cognitive dual task (memory) : The individual is asked to say 3 words that were previously spoken. The time is recorded.

Intervention type: OTHER
Intervention: Functional Balance
Description: It will be assessed with the TUG test. The TUG measures the time it takes for an individual to get up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and sit down again after a ready, go signal.

Intervention type: OTHER
Intervention: Functional Balance
Description: It will be assessed with the TUG test. The TUG measures the time it takes for an individual to get up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and sit down again after a ready, go signal.

Intervention type: OTHER
Intervention: Social Adaptation Assessment
Description: Adaptive behavior will be assessed with the Vineland Adaptive Behavior Scales. It is a parent interview designed to assess functioning in daily life. \[35\]Specifically, adaptive behavior is assessed in four domains: Communication, Daily Living, Socialization and Motor skills. Vineland has reliability and current validity. It has been reported to be sensitive to the difficulties experienced by children with ASD
Study: NCT06359678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NorthStar
Description: Throughout the real-time MRI-guided ablation procedure, the operator will assess the precision of the NorthStar 3D navigation software. Before commencing the actual ablation, the operator will confirm the alignment of the 3D anatomical shell, generated in NorthStar through specific electrical signals. Post the ablation procedure, a secondary alignment verification will be conducted to detect any potential drift or shift.
Study: NCT05102799

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04939974

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic
Description: The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
Study: NCT06777186

Intervention type: OTHER
Intervention: Social Adaptation Assessment
Description: Adaptive behavior will be assessed with the Vineland Adaptive Behavior Scales. It is a parent interview designed to assess functioning in daily life. \[35\]Specifically, adaptive behavior is assessed in four domains: Communication, Daily Living, Socialization and Motor skills. Vineland has reliability and current validity. It has been reported to be sensitive to the difficulties experienced by children with ASD

Intervention type: OTHER
Intervention: Motor skills and proficiency
Description: The Bruininks-Oseretsky Motor Proficiency Test (BOT-2) assesses fine motor, hand coordination, body coordination, strength and agility between the ages of 4-21 years.There are 53 items in the BOT-2. In BOT-2, there are four motor domains including fine motor control, hand coordination, body coordination, strength and agility and a total of eight subtests related to these domains.

Intervention type: OTHER
Intervention: Motor skills and proficiency
Description: The Bruininks-Oseretsky Motor Proficiency Test (BOT-2) assesses fine motor, hand coordination, body coordination, strength and agility between the ages of 4-21 years.There are 53 items in the BOT-2. In BOT-2, there are four motor domains including fine motor control, hand coordination, body coordination, strength and agility and a total of eight subtests related to these domains.
Study: NCT06388291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: ON/OFF stimulation vs OFF/ON stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: ON/OFF stimulation vs OFF/ON stimulation
Study: NCT04795661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenous (IV)
Study: NCT06545136

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FLT201
Description: FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
Study: NCT06775925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral robot-assisted therapy (RT)
Description: RT will be performed as an add-on therapy to the clinical routine therapy scheme for 3 x 30 minutes per week for 6 weeks. RT is applied using the ArmeoSpring, an exoskeleton that provides adjustable antigravity weight support for the arm through a system of springs (no actuators).
Study: NCT06075914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Intervention
Description: Participants will receive ready-to-eat Ketogenic Diet meals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Intervention
Description: Participants will receive ready-to-eat Mediterranean Diet meals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mediterranean Intervention
Description: Participants will receive ready-to-eat Mediterranean Diet meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester
Description: Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
Study: NCT05302596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention